

CADTH Health Technology Review – Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer: Living Systematic Review Version History

Table 1: Key Information Regarding Each Version of this Living Systematic Review

Version Number	Report Version and Update Details
Version 1.0	<p><u>Baseline review:</u></p> <p>Date of initial literature search for baseline review: March 20, 2020</p> <p>Date of final literature search update for baseline review: December 20, 2020</p> <p>Number of included studies in baseline review: 9 unique studies (3 RCTs and 6 nonrandomized studies) in 12 publications¹⁻¹²</p> <p>Publication date: March 30, 2021</p>
	<p><u>Update #1:</u></p> <p>Date of literature search update: March 30, 2021</p> <p>Number of new relevant studies identified in this update: 1 nonrandomized study¹³</p> <p>Assessment of evidence: No important impact on review findings</p> <p>Decision: Integrate later (i.e., in Version 2.0)</p> <p>Review Status: Up to date as of March 30, 2021</p>
	<p><u>Update #2:</u></p> <p>Date of literature search update: June 30, 2021</p> <p>Number of new relevant studies identified in this update: 2 nonrandomized studies^{14,15}</p> <p>Assessment of evidence: No important impact on review findings</p> <p>Decision: Integrate later (i.e., in Version 2.0)</p> <p>Review Status: Up to date as of June 30, 2021</p>
	<p><u>Update #3:</u></p> <p>Date of literature search update: September 30, 2021</p> <p>Number of new relevant studies identified in this update: 0</p> <p>Assessment of evidence: Not applicable</p> <p>Decision: None to integrate</p> <p>Review Status: Up to date as of September 30, 2021</p>
	<p><u>Update #4:</u></p> <p>Date of literature search update: December 30, 2021</p> <p>Number of new relevant studies identified in this update: 0</p> <p>Assessment of evidence: Not applicable</p> <p>Decision: None to integrate</p>

Version Number	Report Version and Update Details
	Review Status: Up to date as of December 30, 2021
Version 2.0	<p>Final review:</p> <p>Date of final literature search update for final review: December 30, 2021</p> <p>Number of included studies in final review: 12 unique studies (3 RCTs and 9 nonrandomized studies) in 15 publications¹⁻¹⁵</p> <p>What's New (from baseline review): New evidence identified from Update #1¹³ and Update #2^{14,15} and assessed to have no important impact on review findings was integrated into the review.</p> <p>Publication date: June 2022</p>

References

- Hurmuz P, Onal C, Ozyigit G, et al. Treatment outcomes of metastasis-directed treatment using (68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). *Strahlenther Onkol.* 2020;196(11):1034-1043.
- Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. *J Clin Oncol.* 2020;38(25):2830-2838.
- Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2020;6(5):650-659.
- van de Ven S, van den Bongard D, Pielkenrood B, et al. Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. *Int J Radiat Oncol Biol Phys.* 2020;107(1):39-47.
- De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. *Eur Urol.* 2019;76(6):732-739.
- Olson R, Senan S, Harrow S, et al. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. *Int J Radiat Oncol Biol Phys.* 2019;105(5):943-947.
- Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet.* 2019;393(10185):2051-2058.
- He Z, Chen G, Ouyang B, et al. Conformal radiation therapy or stereotactic body radiation therapy: Institutional experience in the management of colorectal liver metastases by radiation therapy. *Technol Cancer Res Treat.* 2018;17.
- Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2018;4(1):e173501.
- Lodeweges JE, Klinkenberg TJ, Ubbels JF, Groen HJM, Langendijk JA, Widder J. Long-term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligometastases. *J Thorac Oncol.* 2017;12(9):1442-1445.
- Filippi AR, Guerrero F, Badellino S, et al. Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer. *Clin Oncol (R Coll Radiol).* 2016;28(8):505-512.
- Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? *Radiother Oncol.* 2013;107(3):409-413.
- Liu Y, Zhang Z, Han H, et al. Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. *Front Oncol.* 2021;11:607595.
- Ji X, Zhao Y, He C, et al. Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. *Front Oncol.* 2021;11:659987.
- Buergy D, Wurschmidt F, Gkika E, et al. Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis. *Int J Cancer.* 2021;149(2):358-370.